Worldwide Study Finder

Loading registry information…

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

67 matching registry records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 17:29 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 4Active, not recruitingINTERVENTIONAL

Thymosin Alpha 1 and IgM Levels in Sepsis

ClinicalTrials.gov · NCT07922954 · Registry updated: 2026-11-06

Condition / research focus: Sepsis; Septic Shock
Sponsor: Southeast University, China
Countries with listed sites: China
Registry dates and results: Start: 2026-02-20. Completion: 2027-01-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymalfasin (drug) — also listed as: Thymosin alpha 1, Zadaxin

Where the study takes place — 1 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Zhongda Hospital Southeast University
Nanjing, Jiangsu, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Not applicableCompletedINTERVENTIONAL

Protective Effect of Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA II)

ClinicalTrials.gov · NCT05339529 · Registry updated: 2026-09-14

Condition / research focus: Acute Aortic Syndrome; Aortic Dissection Type A
Sponsor: Nanjing Medical University
Countries with listed sites: China
Registry dates and results: Start: 2022-07-01. Completion: 2026-07-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Thymosin Alpha1, 28A-Glycine-28B-L-Arginine-28C-L-Glutamic Acid-28D-L-Alanine-28E-L-Proline-28F-L-Alanine-28G-L-Asparagine- (drug)
Blank control (drug)

Where the study takes place — 15 listed sites

The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, China
Site recruitment: Not reported
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Site recruitment: Not reported
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
Site recruitment: Not reported
Nanjing First Hospital Nanjing Medical University
Nanjing, Jiangsu, China
Site recruitment: Not reported
Subei People's Hospital of Jiangsu Province
Yangzhou, Jiangsu, China
Site recruitment: Not reported
Qilu Hospital of Shandong University
Jinan, Shandong, China
Site recruitment: Not reported
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Site recruitment: Not reported
The Friendship Hospital of Yili Kazak Autonomous Prefecture
Kazak, Xinjiang, China
Site recruitment: Not reported
The Seventh Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China
Site recruitment: Not reported
The First Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, China
Site recruitment: Not reported
Beijing Anzhen Hospital Capital Medical University
Beijing, China
Site recruitment: Not reported
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, China
Site recruitment: Not reported
The Second Affiliated Hospital of Nanchang University
Nanchang, China
Site recruitment: Not reported
Shanghai East Hospital Tongji University
Shanghai, China
Site recruitment: Not reported
TEDA International Cardiovascular Hospital
Tianjin, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Worldwide Study Finder

Worldwide Study Finder

Find a study

Registry search results

Thymosin Alpha 1 and IgM Levels in Sepsis

Explore the world’s study registries

Worldwide

Africa

Americas

Thymalfasin Combined With Chemotherapy and Immunotherapy in TNBC Neoadjuvant Treatment

Thymosin-α1 for Recurrent Implantation Failure

Thymalfasin for Immune Recovery in Adults With Sepsis

Protective Effect of Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA II)

Study of Adebrelimab Combined With Thymalfasin and Chemotherapy for Neoadjuvant Treatment of Esophageal Cancer

The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC

Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for Locally Advanced Mid-low Rectal Cancer

Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma

TPF Concurrent Chemo-radiotherapy Plus Immunotherapy for Local Advanced Esophageal Squamous Cell Carcinoma

Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients

Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma

Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma

AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection

The Safety, Tolerability, and Efficacy of KD01 in Gynecologic Malignancies

Protective Effect of Ulinastatin and Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA XI)

A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer

A Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade for Limited-stage Small Cell Lung Cancer

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer

Asia

Middle East

Europe

Oceania